Therefore, SOD1 inhibitors, or other antioxidant drugs, may be eligible for use in combination treatment with MET for the MTC-GBM subtype to induce cell-cycle arrest and activation of the apoptotic pathway. The gene discussed is SOD1; the disease is glioblastoma.